Pivotal Point Tracking Tempus AI (TEM): AI Diagnostics Specialist Raises Revenue Outlook After First Quarterly Profit

Tempus AI is a pioneer in personalized medicine, combining artificial intelligence with clinical diagnostics. On August 19, the stock surged significantly, marking a Pivotal Point, driven by a strong Q2 2026. The company achieved its first net profit of $5.6 million with a revenue increase of 22% to $382.5 million. Due to the high momentum in the oncology sector, management raised the annual forecast to up to $1.605 billion. Tempus collaborates with pharmaceutical giants such as AstraZeneca and plans to acquire Personalis for approximately $1.5...